FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3083642009> ?p ?o ?g. }

• W3083642009 endingPage "797" @default.
• W3083642009 startingPage "787" @default.
• W3083642009 abstract "<b><i>Background:</i></b> Although a strong antitumor effect of lenvatinib (LEN) has been noted for patients with unresectable hepatocellular carcinoma (HCC), there are still no reports on the prognosis for patients with disease progression after first-line LEN therapy. <b><i>Methods:</i></b> Patients (<i>n</i> = 141) with unresectable HCC, Child-Pugh class A liver function, and an Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 or 1 who were treated with LEN from March 2018 to December 2019 were enrolled. <b><i>Results:</i></b> One hundred and five patients were treated with LEN as first-line therapy, 53 of whom had progressive disease (PD) at the radiological evaluation. Among the 53 patients with PD, there were 27 candidates for second-line therapy, who had Child-Pugh class A liver function and an ECOG-PS of 0 or 1 at progression. After progression on first-line LEN, 28 patients were treated with a molecular targeted agent (MTA) as second-line therapy (sorafenib: <i>n</i> = 26; ramucirumab: <i>n</i> = 2). Multivariate analysis identified modified albumin-bilirubin grade 1 or 2a at LEN initiation (odds ratio 5.18, 95% confidence interval [CI] 1.465–18.31, <i>p</i> = 0.011) as a significant and independent factor for candidates. The median post-progression survival after PD on first-line LEN was 8.3 months. Cox hazard multivariate analysis showed that a low alpha-fetoprotein level (&#x3c;400 ng/mL; hazard ratio [HR] 0.297, 95% CI 0.099–0.886, <i>p</i> = 0.003), a relative tumor volume &#x3c;50% at the time of progression (HR 0.204, 95% CI 0.07–0.592, <i>p</i> = 0.03), and switching to MTAs as second-line treatment after LEN (HR 0.299, 95% CI 0.12–0.746, <i>p</i> = 0.01) were significant prognostic factors. <b><i>Conclusion:</i></b> Among patients with PD on first-line LEN, good liver function at introduction of LEN was an important and favorable factor related to eligibility for second-line therapy. In addition, post-progression treatment with MTAs could improve the prognosis for patients who had been treated with first-line LEN." @default.
• W3083642009 created "2020-09-11" @default.
• W3083642009 creator A5003790120 @default.
• W3083642009 creator A5012700840 @default.
• W3083642009 creator A5016110387 @default.
• W3083642009 creator A5016338046 @default.
• W3083642009 creator A5018431544 @default.
• W3083642009 creator A5019763674 @default.
• W3083642009 creator A5020608796 @default.
• W3083642009 creator A5022143758 @default.
• W3083642009 creator A5023958825 @default.
• W3083642009 creator A5024813969 @default.
• W3083642009 creator A5026178160 @default.
• W3083642009 creator A5027251663 @default.
• W3083642009 creator A5027695992 @default.
• W3083642009 creator A5031469873 @default.
• W3083642009 creator A5034077858 @default.
• W3083642009 creator A5035029873 @default.
• W3083642009 creator A5042164023 @default.
• W3083642009 creator A5045008956 @default.
• W3083642009 creator A5045968705 @default.
• W3083642009 creator A5048251930 @default.
• W3083642009 creator A5050719404 @default.
• W3083642009 creator A5051242188 @default.
• W3083642009 creator A5053529562 @default.
• W3083642009 creator A5056103416 @default.
• W3083642009 creator A5060789201 @default.
• W3083642009 creator A5074699709 @default.
• W3083642009 creator A5085498187 @default.
• W3083642009 creator A5086880294 @default.
• W3083642009 date "2020-01-01" @default.
• W3083642009 modified "2023-10-01" @default.
• W3083642009 title "Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib" @default.
• W3083642009 cites W1930892342 @default.
• W3083642009 cites W1971837077 @default.
• W3083642009 cites W1994193851 @default.
• W3083642009 cites W2011043511 @default.
• W3083642009 cites W2013804937 @default.
• W3083642009 cites W2019846668 @default.
• W3083642009 cites W2105491035 @default.
• W3083642009 cites W2109202667 @default.
• W3083642009 cites W2119190881 @default.
• W3083642009 cites W2147172608 @default.
• W3083642009 cites W2150141726 @default.
• W3083642009 cites W2179494416 @default.
• W3083642009 cites W2252294506 @default.
• W3083642009 cites W2396589869 @default.
• W3083642009 cites W2560499218 @default.
• W3083642009 cites W2787358630 @default.
• W3083642009 cites W2801863899 @default.
• W3083642009 cites W2908573150 @default.
• W3083642009 cites W2942632018 @default.
• W3083642009 cites W2955378739 @default.
• W3083642009 cites W2961056225 @default.
• W3083642009 cites W4210955410 @default.
• W3083642009 doi "https://doi.org/10.1159/000509387" @default.
• W3083642009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32882687" @default.
• W3083642009 hasPublicationYear "2020" @default.
• W3083642009 type Work @default.
• W3083642009 sameAs 3083642009 @default.
• W3083642009 citedByCount "23" @default.
• W3083642009 countsByYear W30836420092021 @default.
• W3083642009 countsByYear W30836420092022 @default.
• W3083642009 countsByYear W30836420092023 @default.
• W3083642009 crossrefType "journal-article" @default.
• W3083642009 hasAuthorship W3083642009A5003790120 @default.
• W3083642009 hasAuthorship W3083642009A5012700840 @default.
• W3083642009 hasAuthorship W3083642009A5016110387 @default.
• W3083642009 hasAuthorship W3083642009A5016338046 @default.
• W3083642009 hasAuthorship W3083642009A5018431544 @default.
• W3083642009 hasAuthorship W3083642009A5019763674 @default.
• W3083642009 hasAuthorship W3083642009A5020608796 @default.
• W3083642009 hasAuthorship W3083642009A5022143758 @default.
• W3083642009 hasAuthorship W3083642009A5023958825 @default.
• W3083642009 hasAuthorship W3083642009A5024813969 @default.
• W3083642009 hasAuthorship W3083642009A5026178160 @default.
• W3083642009 hasAuthorship W3083642009A5027251663 @default.
• W3083642009 hasAuthorship W3083642009A5027695992 @default.
• W3083642009 hasAuthorship W3083642009A5031469873 @default.
• W3083642009 hasAuthorship W3083642009A5034077858 @default.
• W3083642009 hasAuthorship W3083642009A5035029873 @default.
• W3083642009 hasAuthorship W3083642009A5042164023 @default.
• W3083642009 hasAuthorship W3083642009A5045008956 @default.
• W3083642009 hasAuthorship W3083642009A5045968705 @default.
• W3083642009 hasAuthorship W3083642009A5048251930 @default.
• W3083642009 hasAuthorship W3083642009A5050719404 @default.
• W3083642009 hasAuthorship W3083642009A5051242188 @default.
• W3083642009 hasAuthorship W3083642009A5053529562 @default.
• W3083642009 hasAuthorship W3083642009A5056103416 @default.
• W3083642009 hasAuthorship W3083642009A5060789201 @default.
• W3083642009 hasAuthorship W3083642009A5074699709 @default.
• W3083642009 hasAuthorship W3083642009A5085498187 @default.
• W3083642009 hasAuthorship W3083642009A5086880294 @default.
• W3083642009 hasConcept C126322002 @default.
• W3083642009 hasConcept C143998085 @default.
• W3083642009 hasConcept C156957248 @default.
• W3083642009 hasConcept C207103383 @default.
• W3083642009 hasConcept C2776264508 @default.

• next